The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer

Sandro Pignata, Giovanni Scambia, Domenica Lorusso, Ugo De Giorgi, Maria Ornella Nicoletto, Rossella Lauria, Anna Maria Mosconi, Cosimo Sacco, Claudia Omarini, Pierosandro Tagliaferri, Maria Gabriella Ferrandina, Saverio Cinieri, Antonella Savarese, Giorgio Valabrega, Carmela Pisano, Vanda Salutari, Francesco Raspagliesi, Barbara Kopf, Sabrina Chiara Cecere, Giulia AmadioGiuseppa Maltese, Marilena Di Napoli, Stefano Greggi, Simona Signoriello, Gennaro Daniele, Alessandra Sacco, Simona Losito, Nicola Normanno, Francesco Perrone, Ciro Gallo, Maria Carmela Piccirillo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

8 Citazioni (Scopus)


BACKGROUND: Cervical cancer cells often express Epidermal Growth Factor Receptor (EGFR). Cetuximab (CET), an anti-EGFR antibody, can be safely combined with carboplatin (C) and paclitaxel (P), a standard treatment for advanced/recurrent cervical cancer (ARCC) patients. PATIENTS AND METHODS: ARCC patients, ECOG PS ≤ 1, were randomized to CP for 6 cycles with or without CET (400 mg/m2 one week before starting CP, then 250 mg/m2 weekly) until disease progression or unacceptable toxicity. Event-free survival (EFS) was the primary endpoint. With a 4.5 months expected median EFS and a 6.4 months predicted EFS (HR 0.70), 0.20 one-tailed α and 80% power, 89 events were required for the final intent-to-treat analysis. RESULTS: 108 patients were assigned to CP (n = 53) or CP-CET (n = 55). Median age was 50, 69% were PS0, 76% had recurrent disease, 91% had distant metastasis and 57% had received previous chemotherapy. After a median follow-up of 23 months, 102 patients had an event, 97 progressed and 61 died. Median EFS was 4.7 and 6.0 months (one-tail P = 0.43), median PFS was 5.2 and 7.6 months (one-tail P = 0.20) and median OS was 17.7 and 17 months (one-tail P = 0.27), with CP and CP-CET, respectively. There was no difference in the occurrence of severe adverse events, except for skin toxicity. Biomarker analysis, in a small subgroup of patients, suggests that PIK3CA mutation might be predictive of CET resistance. CONCLUSION: CP-CET was not more active than CP alone in unselected ARCC patient
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaGynecologic Oncology
Stato di pubblicazionePubblicato - 2019


  • Cervical cancer
  • Cetuximab
  • PIK3CA mutation
  • Randomized phase 2


Entra nei temi di ricerca di 'The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer'. Insieme formano una fingerprint unica.

Cita questo